- Biotech company Immutep (IMM) has been granted a patent for its cancer drug, Eftilagamod Alpha (Efti), by the U.S. Patent and Trademark Office
- This new patent follows the grant of the corresponding European patent in November 2018
- The patent is particularly significant as it covers both phase two TACTI-002 and phase one TACTI-mel trials
- The patent will expire on January 8, 2036
- IMM is trading up 6.41 per cent at 41.5 cents
Biotech company Immutep (IMM) has been granted a patent for its cancer drug, Eftilagamod Alpha (Efti), by the United States Patent and Trademark Office
This U.S. patent follows the grant of the corresponding European patent announced in November 2018. The claims of the patent protect Immutep’s intellectual property relating to its lead active immunotherapy candidate and a Programmed Cell Death (PD-1) pathway inhibitor.
This new patent is particularly significant for the company as it covers the phase two TACTI-002 and phase one TACTI-mel trials.
Immutep is a biotechnology company focusing on the development of Lymphocyte Activation Gene-3 (LAG-3)-related immunotherapeutic products for treating cancer and autoimmune disease.
The company hopes use its technology and expertise to bring innovative treatment options to market for patients. Immutep is dual-listed on the Australian Securities Exchange and the NASDAQ in the United States
“We are very pleased that this United States patent has been granted covering our lead product candidate, efti, in combination with key anti-PD-1 therapies,” Immutep CEO Mark Voigt commented.
“This is particularly so in view of the highly encouraging data we have seen from both our TACTI (Two Active Immunotherapies) trials which evaluate efti in combination with pembrolizumab,” he continued.
“Furthermore, this new patent and patent applications in other key markets continue to underpin our ongoing investment in clinical development.”
The patent will expire on January 8, 2036.
Immutep was up 6.41 per cent at 41.5 cents at 10.11 am AEDT.